Persons with laboratory-confirmed history of dengue in their medical records can be considered to receive Dengvaxia, without the need of serotesting. Therefore a well-established database of confirmed [Read More...]
Symptoms of Covid and acute dengue can be similar. Timely laboratory diagnosis (such as PCR) is the key to differentiate these two infections.
Yes. Many epidemiological factors such as population growth, global climate change, increased urbanization, migration and international trade can increase the proliferation and expansion of mosquito vectors (Grange [Read More...]
CYD-TDV has demonstrated prevention against symptomatic infections, as well as asymptomatic infections. Consequently, it could contribute to reducing viral transmission and thus to indirect protection if the [Read More...]
During the Active Phase of CYD14, efficacy by country was consistent with the overall estimate the VE against VCD. The point estimates of VE in Thailand was [Read More...]
This person doesn't need to repeat the first dose and continue to receive the 2nd dose.
In the indicated population, the most common side effects of the vaccine (any severity/grade) include headache, injection-site pain, malaise and myalgia. These side effects are usually mild [Read More...]
Dengvaxia must not be administered to individuals with congenital or acquired immune deficiency that impairs cell-mediated immunity, including immunosuppressive therapies such as chemotherapy or high doses of [Read More...]
Dengue history must be based on a recorded laboratory confirmation of past acute infection, which could have been tested at the time of infection by a direct [Read More...]